3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
29
Unknown
2
Withdrawn
1
Sponsor Class
OTHER
3
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Neoplasms
83
Carcinoma, Non-Small-Cell Lung
79
Breast Neoplasms
71
Leukemia, Myeloid, Acute
39
Colorectal Neoplasms
37
Recurrence
36
Prostatic Neoplasms
34
Neoplasm Metastasis
30
Multiple Myeloma
28
Lymphoma
26
Pancreatic Neoplasms
25
Melanoma
25
Lymphoma, Non-Hodgkin
24
Lung Neoplasms
24
Leukemia, Lymphocytic, Chronic, B-Cell
23
Ovarian Neoplasms
22
Lymphoma, Follicular
22
Carcinoma, Hepatocellular
22
Carcinoma, Renal Cell
21
Stomach Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
19
Lymphoma, Large B-Cell, Diffuse
19
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Myelodysplastic Syndromes
18
Leukemia
18
Head and Neck Neoplasms
18
Urinary Bladder Neoplasms
17
Hematologic Neoplasms
14
Carcinoma
13
Uterine Cervical Neoplasms
12
Interventions
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
INDUSTRY
×
Acquired Immunodeficiency Syndrome
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn